Clinical Trials Logo

Clinical Trial Summary

The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of nasopharyngeal cancer.

Clinical Trial Description

By enrolling patients with small metastases of nasopharyngeal cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of high-activity natural killer cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS). ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03007836
Study type Interventional
Source Fuda Cancer Hospital, Guangzhou
Status Completed
Phase Phase 1/Phase 2
Start date December 1, 2016
Completion date June 1, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03813394 - Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC Phase 1/Phase 2